We love it the way it is right now, and for this reason, we would love it if things continued in the same way. This sentiment captures the mindset of Danish pharmaceutical firm Novo Nordisk's CEO Lars Fruergaard Jørgensen.
"I hope Eli Lilly will be up for the competition and do well. I don't see either of us taking over complete dominance of the market by having a hugely differentiated product," says Fruergaard Jørgensen.
Already a subscriber? Log in.
Read the whole article
Get access for 14 days for free.
No credit card is needed, and you will not be automatically signed up for a paid subscription after the free trial.
- Access all locked articles
- Receive our daily newsletters
- Access our app
Get full access for you and your coworkers.
Start a free company trial todayMore from MedWatch
Thousands of collaborative research papers with China pose threat to Europe, authorities worry
Research collaborations with China, including those in the life science sector, are being put under the microscope as defense authorities express concerns about Chinese espionage in Europe.
Orphazyme's creditors to vote on sales agreement at end of May
Sunday’s sales agreement between US-based Kempharm and Orphazyme will be decided on May 30, when the company’s creditors meet to vote on the proposal.
Diabetes center CEO: New Eli Lilly drug is worthy opponent for Novo Nordisk's Ozempic
Allan Flyvbjerg, CEO of Steno Diabetes Center in Copenhagen, says Eli Lilly’s tirzepatide has proved itself a fierce challenger to Novo Nordisk’s newest generation of diabetes drugs.
In a world of options, Genmab's CEO chose partnerships
In 2015, Genmab partnered with relatively unknown biotech firm Biontech. Reflecting on how far Genmab has come since, CEO Jan van de Winkel is still confident that partnerships, rather than acquisitions, are the way forward. If it had acquired Biontech at the time, the CEO speculates Genmab may have put a stop to other activities – including the Covid-19 vaccine efforts that went on to save millions of lives. This and fairness are worth remembering as biotech firms are increasingly strapped for cash, van de Winkel reflects.
Novo Holdings establishes new firm managed by biotech veterans
Co-Founder and former CSO of Orphazyme Thomas Kirkegaard Jensen and Bo Rode Hansen, CEO of Scandion Oncology, are both involved in another secret venture backed by Novo Holdings.
Senior Manager, Clinical Trial Budget 
Account Manager 
Procurement Process Excellence Specialist 
Key Account Manager, Europe and Asia 
KLIFO is looking for a Clinical Supply Manager for our Glostrup office 
IT Solution Architect for R&D and Global Quality applications 
Director Global Engineering 
Consultant Manager 
Analytical Senior Scientist 
Clinical Trial Administrator 
Communications Consultant 
Client Talent Acquisition Specialist 
Clinical Project Manager 
Director for innovative pre-clinical testing unit 
Nordic Medical Affairs Manager